53709.1 IP-LS

Résumé

AlvireX: A game-changing translational drug screening platform to revolutionize drug development against respiratory viral infections

Textes supplémentaires

Abstract

The consortium will develop AlvireX - a novel drug screening platform that will accelerate and improve drug development for respiratory viruses, such as SARS-CoV-2. Here, we will deliver the first AlvireX kit tailored to COVID-19 research, which will be ready to enter the market in Q1 2023.

Participants

Nina Hobi

Wirtschaftspartner

AlveoliX AG CHE-475.985.759 Nina Hobi Murtenstrasse 50 3008 Bern BE CH

Marianna Kruithof-de Julio

Kontaktperson

Universität Bern DBMR Marianna Kruithof-de Julio Murtenstrasse 35 3008 Bern BE CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2021-07-31
Date de fin: 2023-07-31
Coûts totaux approuvés: CHF 559931.55
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

T490 Biotechnology 100.0%